← Back to Search

Alpha-7 nAChR Antagonist

[F18]-ASEM + Contingency Management for Tobacco Use Disorder

Phase 1
Waitlist Available
Led By Elise Weerts, Ph.D.
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial will study if nicotine-dependent smokers show changes in the α7 nicotinic acetylcholine receptor (nAChR) when compared to controls, and if this influences measures of tobacco abstinence.

Eligible Conditions
  • Tobacco Use Disorder
  • Tobacco Smoking

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Craving/Urge to smoke as determined via the Questionnaire of Subjective Urges (QSU)
Distribution volume (VT) as determined by [18F]-ASEM PET scan
Total withdrawal score on the Minnesota Nicotine Withdrawal Scale (MNWS)
Secondary outcome measures
Attention as assessed by Connors continuous performance task
Negative mood as determined by the Positive and negative affect scale (PANAS)
Number of Cigarettes smoked per day
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: [F18]-ASEM + Contingency ManagementExperimental Treatment2 Interventions
PET radiopharmaceutical 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6 [18F]fluorodibenzo[b,d]thiophene 5,5-dioxide with incentive payments.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)
2019
Completed Phase 1
~20
Contingency Management
2014
Completed Phase 2
~3430

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,274 Previous Clinical Trials
14,840,503 Total Patients Enrolled
17 Trials studying Tobacco Use Disorder
4,334 Patients Enrolled for Tobacco Use Disorder
National Institute on Drug Abuse (NIDA)NIH
2,488 Previous Clinical Trials
2,622,637 Total Patients Enrolled
272 Trials studying Tobacco Use Disorder
49,010 Patients Enrolled for Tobacco Use Disorder
Elise Weerts, Ph.D.Principal InvestigatorJohns Hopkins University
2 Previous Clinical Trials
55 Total Patients Enrolled
~3 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top